Randomized Controlled Study Comparing Colon Evaluation With The Pure-Vu System To A Standard Colonoscopy In Patients Who Are High Risk For Inadequate Bowel Preparation (RESCue)
Primary Purpose
Gastrointestinal Disease, Colorectal Cancer
Status
Withdrawn
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Pure-Vu System
Sponsored by
About this trial
This is an interventional screening trial for Gastrointestinal Disease focused on measuring colonoscopy
Eligibility Criteria
Inclusion Criteria:
- Adults > age 22
- Elective outpatient colonoscopy by participating gastroenterologist
- Stool clarity grade 1-3 at presentation for colonoscopy
Exclusion Criteria:
- Not competent to consent
- Bleeding disorder - known or suspected
- Hereditary Gastrointestinal Cancer syndrome
- Known PT INR > 1.5
- Know elevated PTT
- Anti-platelet agent or anticoagulant (other than aspirin or nonsteroidal agent) which has not been stopped for the colonoscopy
- Known platelet count < 50,000
- Known absolute neutrophil count < 1,000
- History of surgical colon resection
- Pre-colonoscopy intent to enter terminal ileum
- Prior incomplete colonoscopy due to technical & non-bowel preparation related reasons
- Regular use of non-topical steroid
- Pregnant
- Prisoner or institutionalized for any reason
- Psychiatric illness greater than mild
- Colonoscopy without anesthesia administered (MAC) sedation
- Diverticulitis
- Active inflammatory bowel disease (Crohn's, Ulcerative Colitis, or Indeterminate)
- Known or suspected colon stricture
Sites / Locations
- Washington University in St. Louis
Arms of the Study
Arm 1
Arm 2
Arm Type
No Intervention
Other
Arm Label
standard Colonoscopy
Pure-Vu System
Arm Description
Control arm Colonoscopy procedure using standard flushing and suctioning - standard of care
Intervention - Colonoscopy procedure using Pure-Vu System
Outcomes
Primary Outcome Measures
rate of adequate cleansing level after using the Pure-Vu System as compare to sandard of care colonoscopy procedure
A comparison between the two study arms (i.e., Pure-Vu vs. standard colonoscopy) of the rate of overall cleansing as well as cleansing per segment will be evaluated by the BBPS scoring index (Bowel preparation adequacy defined as BBPS >2 in each segment)
Secondary Outcome Measures
Full Information
NCT ID
NCT04285008
First Posted
February 24, 2020
Last Updated
June 23, 2020
Sponsor
Motus GI Medical Technologies Ltd
1. Study Identification
Unique Protocol Identification Number
NCT04285008
Brief Title
Randomized Controlled Study Comparing Colon Evaluation With The Pure-Vu System To A Standard Colonoscopy In Patients Who Are High Risk For Inadequate Bowel Preparation
Acronym
RESCue
Official Title
Randomized Controlled Study Comparing Colon Evaluation With The Pure-Vu System To A Standard Colonoscopy In Patients Who Are High Risk For Inadequate Bowel Preparation
Study Type
Interventional
2. Study Status
Record Verification Date
June 2020
Overall Recruitment Status
Withdrawn
Why Stopped
Sponsor has terminated study due to COVID-19 related concerns
Study Start Date
March 3, 2020 (Actual)
Primary Completion Date
April 1, 2021 (Anticipated)
Study Completion Date
April 15, 2021 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Motus GI Medical Technologies Ltd
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The primary objective of this multi-center, prospective, randomized controlled trial is to evaluate the bowel cleansing after Pure-Vu use in outpatient subjects at high risk for inadequate colon preparation as compare to standard of care.
Detailed Description
Total of 88 subjects (44 per arm) at high risk for inadequate colon preparation will be randomized and undergo procedure either in the Control arm (standard of care) or with the Pure-Vu System.
Subjects will be enrolled at up to 4 clinical sites in the United States.
primary endpoint- A comparison between the two study arms (i.e., Pure-Vu vs. standard colonoscopy) of the rate of overall cleansing as well as cleansing per segment will be evaluated by the BBPS scoring index (Bowel preparation adequacy defined as BBPS >2 in each segment)
The following secondary endpoints will be determined:
Assess the willingness of consented subjects to pay for Pure-Vu prior to colonoscopy
Colonoscopy procedural measures for Intervention and Control arms
Endoscopists' experience
Safety assessment for all subjects on the day of procedure per endoscopist
Post-colonoscopy patient experience and safety check with scripted phone call 1-3 days after colonoscopy
Assess the willingness of consented subjects to pay for the Pure-Vu System 1-3 days after colonoscopy
Follow-up call will be conducted 1-3 business days after the procedure to verify that there has been no change in their clinical status and record their willingness to use the Pure-Vu System in the future.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gastrointestinal Disease, Colorectal Cancer
Keywords
colonoscopy
7. Study Design
Primary Purpose
Screening
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Randomization to Intervention or Control arm will use stratification by site, endoscopist and blocking. Sites are expected to contribute approximately equal numbers of procedures, and no site will be allowed to contribute more than 50% of the target sample size. The randomization sequences will be provided in advance by the study's statistician using an online system to obtain the randomization assignment and the corresponding colonoscope will be prepared. Randomization assignment will be recorded for each subject.
Masking
Participant
Masking Description
The Colonoscope will be prepared as per normal routine and the research assistant will cover the colonoscope before the patient enters the endoscopy room to keep him/her blinded to the study arm. This is uncovered once the patient is sedated.
Allocation
Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
standard Colonoscopy
Arm Type
No Intervention
Arm Description
Control arm
Colonoscopy procedure using standard flushing and suctioning - standard of care
Arm Title
Pure-Vu System
Arm Type
Other
Arm Description
Intervention - Colonoscopy procedure using Pure-Vu System
Intervention Type
Device
Intervention Name(s)
Pure-Vu System
Intervention Description
The Pure-Vu System is Food and Drug Administration (FDA) approved device (K191220), intended to connect to standard colonoscopes to help facilitate intra-procedural cleaning of a poorly prepared colon by irrigating or cleaning the colon and evacuating the irrigation fluid (water), feces and other bodily fluids and matter, e.g. blood.
Primary Outcome Measure Information:
Title
rate of adequate cleansing level after using the Pure-Vu System as compare to sandard of care colonoscopy procedure
Description
A comparison between the two study arms (i.e., Pure-Vu vs. standard colonoscopy) of the rate of overall cleansing as well as cleansing per segment will be evaluated by the BBPS scoring index (Bowel preparation adequacy defined as BBPS >2 in each segment)
Time Frame
Up to 2 hours
10. Eligibility
Sex
All
Minimum Age & Unit of Time
22 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Adults > age 22
Elective outpatient colonoscopy by participating gastroenterologist
Stool clarity grade 1-3 at presentation for colonoscopy
Exclusion Criteria:
Not competent to consent
Bleeding disorder - known or suspected
Hereditary Gastrointestinal Cancer syndrome
Known PT INR > 1.5
Know elevated PTT
Anti-platelet agent or anticoagulant (other than aspirin or nonsteroidal agent) which has not been stopped for the colonoscopy
Known platelet count < 50,000
Known absolute neutrophil count < 1,000
History of surgical colon resection
Pre-colonoscopy intent to enter terminal ileum
Prior incomplete colonoscopy due to technical & non-bowel preparation related reasons
Regular use of non-topical steroid
Pregnant
Prisoner or institutionalized for any reason
Psychiatric illness greater than mild
Colonoscopy without anesthesia administered (MAC) sedation
Diverticulitis
Active inflammatory bowel disease (Crohn's, Ulcerative Colitis, or Indeterminate)
Known or suspected colon stricture
Facility Information:
Facility Name
Washington University in St. Louis
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Randomized Controlled Study Comparing Colon Evaluation With The Pure-Vu System To A Standard Colonoscopy In Patients Who Are High Risk For Inadequate Bowel Preparation
We'll reach out to this number within 24 hrs